Adverum Biotechnologies
Biotechnology ResearchView the employees at
Adverum Biotechnologies-
Shelly Plapp Senior Director, Regulatory Affairs, Operations at Adverum Biotechnologies, Inc.
-
Greater Chicago Area
-
Top 10%
Joleen Morgan Paralegal Specialist | Securities | Corporate Governance-
San Francisco Bay Area
-
Top 10%
Romina Avram Moore Director, HRBP at Adverum Biotechnologies, Inc.-
San Francisco Bay Area
-
Rising Star
Martin Lee IT Professional | Technology Enthusiast | Educator |-
San Francisco Bay Area
-
Rising Star
Overview
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
-